homoscedasticity assumption in RSABE method [RSABE / ABEL]

posted by WinnieH – Sweden, 2023-08-18 10:57 (301 d 06:04 ago) – Posting: # 23697
Views: 1,801

Dear all,

I had a question related to the homoscedasticity assumption in the RSABE method when I read the tutorial of PowerTOST.
PowerTOST-RSABE

If the RSABE method is performed on the highly variable drug with the 4-way crossover design (not the NTI drug), is the homoscedasticity assumption always holden? And I think if a 3-way crossover design is used, there is no way to assume the homoscedasticity since the test drug is administered once and we can not calculate the WSV of the test drug.

A further question is, when do we assume the reference and test product have equal variances, i.e. CVwT ≡ CVwR? And why?

Thank you so much and looking forward to your reply!

Winnie


Edit: Category changed; see also this post #1[Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,056 posts in 4,840 threads, 1,641 registered users;
142 visitors (0 registered, 142 guests [including 60 identified bots]).
Forum time: 17:01 CEST (Europe/Vienna)

Exploratory analysis: The art of finding a Rembrandt
in a Jackson Pollock.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5